Connect
MJA
MJA

Potential pitfalls in the diagnosis of phaeochromocytoma

Jane L Harding, Michael W Yeh, Leigh W Delbridge, Stan B Sidhu and Bruce G Robinson
Med J Aust 2005; 182 (12): . || doi: 10.5694/j.1326-5377.2005.tb06852.x
Published online: 20 June 2005

Six patients being evaluated for phaeochromocytoma had misleading investigative findings: all initially had raised urinary catecholamine levels, and five had adrenal masses on imaging studies. Adrenalectomy in these five patients revealed only one pathologically confirmed phaeochromocytoma. Tricyclic antidepressant use produced misleading elevations in urinary catecholamine levels in three patients. 24-hour urine studies should be performed at least twice, after eliminating confounding factors (stressors, medications).

The details of six patients treated in the period April 1999 – October 2003 by members of the Section of Endocrine Surgery of the Royal Australasian College of Surgeons are outlined in Box 1. In all patients, clinical suspicion of phaeochromocytoma was raised by the presence of hypertension, paroxysmal symptoms, or both. Twenty-four-hour urinary catecholamine levels were found to be elevated, although in Patients 1–5 these abnormalities were confined to one or two analytes only. In all except Patient 2, adrenal lesions were discovered on imaging, with large haemorrhagic masses detected in patients with an acute presentation (Patients 5 and 6). Patients with abnormalities on computed tomography (CT) underwent surgery. In Patients 1, 3, and 4, the excised tissues were found to be pathologically normal or to show mild enlargement (benign). In Patients 5 and 6, blood clot and necrotic tissue comprised the bulk of the specimens (Box 2), with a phaeochromocytoma discovered in the latter patient. Of note, Patients 1–3 were receiving tricyclic antidepressants for non-standard uses that did not include the treatment of major depression.


  • 1 University of Sydney, Endocrine Surgical Unit, Royal North Shore Hospital, St Leonards, NSW.
  • 2 University of Sydney, Department of Endocrinology, Royal North Shore Hospital, St Leonards, NSW.


Correspondence: 

Acknowledgements: 

We thank Dr Maxwell Coleman (St Vincent’s Hospital, Sydney) and Dr Lionel Hartley (Princess Alexandra Hospital Endocrine Unit, Sydney) for their contribution of cases.

Competing interests:

None identified.

  • 1. O’Connor DT. The adrenal medulla, catecholamines and pheochromocytoma. In: Goldman L, Bennett JC, editors. Cecil textbook of medicine. Philadelphia, PA: WB Saunders Company, 2000: 1259.
  • 2. Manger WM, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 2004; 6: 477-484.
  • 3. Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore) 1991; 70: 46-66.
  • 4. Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 2001; 134: 315-329.
  • 5. Kudva YC, Sawka AM, Young WF Jr. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003; 88: 4533-4539.
  • 6. Eisenhofer G, Goldstein DS, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003; 88: 2656-2666.
  • 7. Grumbach MM, Biller BM, Braunstein GD, et al. Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med 2003; 138: 424-429.
  • 8. Jacobs LM, Williams LF, Hinrichs HR. Hemorrhage into a pheochromocytoma. JAMA 1978; 239: 1156.
  • 9. Lehman DJ Jr, Rosof J. Massive hemorrhage into an adrenal pheochromocytoma. N Engl J Med 1956; 254: 474-476.
  • 10. Lenders JW, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 2002; 287: 1427-1434.
  • 11. Krentz AJ, Mikhail S, Cantrell P, Hill GM. Drug points: pseudophaeochromocytoma syndrome associated with clozapine. BMJ 2001; 322: 1213.
  • 12. Swedberg K, Bristow MR, Cohn JN, et al. Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure. Circulation 2002; 105: 1797-1803.
  • 13. Veith RC, Lewis N, Linares OA, et al. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry 1994; 51: 411-422.
  • 14. Neumann HP. Imaging vs biochemical testing for pheochromocytoma. JAMA 2002; 288: 314-315 (author reply: 315).

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.